Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.2805
-0.0145 (-4.92%)
Jun 20, 2025, 4:00 PM - Market closed
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
9.42M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
Dec 31, 2021 | 449.00K | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CLDI News
- 4 weeks ago - Innovation In Indexing: Why Passive ETFs Matter - ETF Trends
- 2 months ago - Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - GlobeNewsWire
- 2 months ago - Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds - PRNewsWire
- 2 months ago - Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire
- 3 months ago - Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire
- 3 months ago - Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform - GlobeNewsWire
- 4 months ago - Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 4 months ago - Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital - GlobeNewsWire